CME Presentations

Atopic Dermatitis: A Dual Approach to Collaborative Care and Disease Control


Presentations


CME Information

Atopic Dermatitis: A Dual Approach to Collaborative Care and Disease Control


PIM LogoPQH Logo

Aligning Treatment with Disease Burden and Severity to Optimize Success

  • Combine information gathered from clinical examination and evaluation of disease burden to confirm a diagnosis and determine disease severity in children, adolescents and adults with AD
  • Describe how targeted treatment options overcome the limitations of traditional topical and systemic treatments and result in improved symptom control and QoL outcomes for people with AD and their caregivers
  • Integrate components of shared decision-making that includes ongoing assessment of QoL, symptoms and disease severity for monitoring of progress with prompt adjustment of treatment to achieve patient’s preferred goals

Atopic Dermatitis: A Clear Roadmap to Treatment Success

  • Combine information gathered from clinical examination and evaluation of disease burden to confirm a diagnosis and determine disease severity in children, adolescents and adults with AD
  • Describe how targeted treatment options overcome the limitations of traditional topical and systemic treatments and result in improved symptom control and QoL outcomes for people with AD and their caregivers
  • Integrate components of shared decision-making that includes ongoing assessment of QoL, symptoms and disease severity for monitoring
Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals

TUITION

Complimentary JointlyAccreditedProvider Logo

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

LIVE CREDIT DESIGNATION STATEMENTS

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Aligning Treatment with Disease Burden and Severity to Optimize Success
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-20-2215-L01-P)
Type of Activity: Knowledge

Atopic Dermatitis: A Clear Roadmap to Treatment Success
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-20-2216-L01-P)
Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hours.

ENDURING CREDIT DESIGNATION STATEMENTS

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Aligning Treatment with Disease Burden and Severity to Optimize Success
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-20-2217-H01-P)
Type of Activity: Knowledge

Atopic Dermatitis: A Clear Roadmap to Treatment Success
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-20-2218-H01-P)
Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hours.

DATE OF RELEASE/EXPIRATION

Live Activities

Thursday, September 17, 2020 from 2:00pm – 3:00pm ET
Aligning Treatment with Disease Burden and Severity to Optimize Success

Thursday, September 17, 2020 from 3:00pm – 4:00pm ET
Atopic Dermatitis: A Clear Roadmap to Treatment Success

Enduring Material

The enduring material will be available from September 17, 2020 to September 17, 2021

TARGET AUDIENCE

This activity is intended for allergists, dermatologists, primary care physicians, pediatricians, advanced practitioners, pharmacists, and nurses.

ESTIMATED TIME TO COMPLETE

This activity consists of 2 sessions which should take approximately 2 hours to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.ImmunologyLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test. For Pharmacists: Upon receipt of the completed activity evaluation form credit will be submitted to the NABP CPE Monitor Service. Pharmacists will need to provide their National Association of Boards of Pharmacy (NABP) e-Profile ID and date of birth (MMDD) to ensure the data is submitted to the ACPE and NABP properly. If you need to obtain your NABP e-Profile, please visit www.nabp.net.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship
Peter A. Lio, MD
Clinical Assistant Professor of Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Royalty: Theraplex AIM, Theraplex company
Receipt of Intellectual Property Rights/Patent Holder: Patent Pending, Theraplex AIM, Theraplex company
Consulting Fee: UCB, Dermavant, Regeneron/Sanofi, Dermira, Pfizer, LEO, AbbVie, Kiniksa, Eli Lilly, Micreos, L’Oreal, Pierre-Fabre, J & J, Unilever, Menlo, Intraderm, AO Biome, Realm, Altus, Verrica, Arbonne, Amyris, Bodewell, Burt’s Bees
Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents: Regeneron/Sanofi, Pfizer, L’Oreal
Contracted Research: AbbVie, Regeneron/Sanofi
Ownership Interest less than 5%: Micreos, Altus Labs
Other: Board Member, National Eczema Association (non-monetary)
Paul P. Doghramji, MD, FAAFP
Medical Director of Health Services,
Ursinus College;
Senior Family Practice Physician,
Collegeville Family Practice
Consulting Fee: Eisai, Jazz
Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents: Eisai, Allergan, Harmony
Ownership Interest less than 5%: Pfizer
Kafi Brown
Public Relations Director
Asthma & Allergy Foundation of America
None

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Carole Drexel
Medical Director
PlatformQ Health Education, LLC
None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Elizabeth del Nido, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: Please contact the Postgraduate Institute for Medicine at www.pimed.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@ImmunologyLive.com.